These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38886525)

  • 1. Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
    Chapeau EA; Sansregret L; Galli GG; Chène P; Wartmann M; Mourikis TP; Jaaks P; Baltschukat S; Barbosa IAM; Bauer D; Brachmann SM; Delaunay C; Estadieu C; Faris JE; Furet P; Harlfinger S; Hueber A; Jiménez Núñez E; Kodack DP; Mandon E; Martin T; Mesrouze Y; Romanet V; Scheufler C; Sellner H; Stamm C; Sterker D; Tordella L; Hofmann F; Soldermann N; Schmelzle T
    Nat Cancer; 2024 Jul; 5(7):1130. PubMed ID: 38886525
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
    Chapeau EA; Sansregret L; Galli GG; Chène P; Wartmann M; Mourikis TP; Jaaks P; Baltschukat S; Barbosa IAM; Bauer D; Brachmann SM; Delaunay C; Estadieu C; Faris JE; Furet P; Harlfinger S; Hueber A; Jiménez Núñez E; Kodack DP; Mandon E; Martin T; Mesrouze Y; Romanet V; Scheufler C; Sellner H; Stamm C; Sterker D; Tordella L; Hofmann F; Soldermann N; Schmelzle T
    Nat Cancer; 2024 Jul; 5(7):1102-1120. PubMed ID: 38565920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging Hot Spots of TEAD-Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling.
    Zhao B; Pobbati AV; Rubin BP; Stauffer S
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Inhibition of the YAP : TEAD Interaction: An Unprecedented Drug Discovery Challenge.
    Chène P
    ChemMedChem; 2024 Jun; ():e202400361. PubMed ID: 38863297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.
    Garcia-Rendueles ME; Ricarte-Filho JC; Untch BR; Landa I; Knauf JA; Voza F; Smith VE; Ganly I; Taylor BS; Persaud Y; Oler G; Fang Y; Jhanwar SC; Viale A; Heguy A; Huberman KH; Giancotti F; Ghossein R; Fagin JA
    Cancer Discov; 2015 Nov; 5(11):1178-93. PubMed ID: 26359368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 7. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.
    Zhou W; Li Y; Song J; Li C
    Anal Biochem; 2019 Dec; 586():113413. PubMed ID: 31479631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
    Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
    Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RHOA activity in expanding blastocysts is essential to regulate HIPPO-YAP signaling and to maintain the trophectoderm-specific gene expression program in a ROCK/actin filament-independent manner.
    Marikawa Y; Alarcon VB
    Mol Hum Reprod; 2019 Feb; 25(2):43-60. PubMed ID: 30395288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YAP inhibits ERα and ER
    Li X; Zhuo S; Zhuang T; Cho YS; Wu G; Liu Y; Mu K; Zhang K; Su P; Yang Y; Zhang CC; Zhu J; Jiang J
    Nat Commun; 2022 Jun; 13(1):3075. PubMed ID: 35654829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways.
    Pham TH; Hagenbeek TJ; Lee HJ; Li J; Rose CM; Lin E; Yu M; Martin SE; Piskol R; Lacap JA; Sampath D; Pham VC; Modrusan Z; Lill JR; Klijn C; Malek S; Chang MT; Dey A
    Cancer Discov; 2021 Mar; 11(3):778-793. PubMed ID: 33208393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.
    Fan M; Lu W; Che J; Kwiatkowski NP; Gao Y; Seo HS; Ficarro SB; Gokhale PC; Liu Y; Geffken EA; Lakhani J; Song K; Kuljanin M; Ji W; Jiang J; He Z; Tse J; Boghossian AS; Rees MG; Ronan MM; Roth JA; Mancias JD; Marto JA; Dhe-Paganon S; Zhang T; Gray NS
    Elife; 2022 Oct; 11():. PubMed ID: 36300789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth.
    Li X; Zhuo S; Cho YS; Liu Y; Yang Y; Zhu J; Jiang J
    EMBO J; 2023 Feb; 42(4):e112184. PubMed ID: 36588499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The First Class of Small Molecules Potently Disrupting the YAP-TEAD Interaction by Direct Competition.
    Furet P; Bordas V; Le Douget M; Salem B; Mesrouze Y; Imbach-Weese P; Sellner H; Voegtle M; Soldermann N; Chapeau E; Wartmann M; Scheufler C; Fernandez C; Kallen J; Guagnano V; Chène P; Schmelzle T
    ChemMedChem; 2022 Oct; 17(19):e202200303. PubMed ID: 35950546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive
    Nouri K; Azad T; Ling M; Janse van Rensburg HJ; Pipchuk A; Shen H; Hao Y; Zhang J; Yang X
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
    Miesfeld JB; Link BA
    Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD.
    Mesrouze Y; Bokhovchuk F; Meyerhofer M; Fontana P; Zimmermann C; Martin T; Delaunay C; Erdmann D; Schmelzle T; Chène P
    Elife; 2017 Apr; 6():. PubMed ID: 28430104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
    Wang M; Yan Q; Song Y; Zhang Z; Chen X; Gao K; Wan X
    Oncogene; 2023 Jan; 42(4):322-334. PubMed ID: 36446891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.